Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

Sustainable Development

Sustainable Development

As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.

Language Development

Language Development

Children master language quickly and with relative ease, supported by both biological predisposition and reinforcement. B. F. Skinner (1957) proposed that language is learned through reinforcement, while Noam Chomsky (1965) argued that language acquisition mechanisms are biologically determined.
The critical period for language acquisition suggests that the ability to acquire language is at its peak early in life. As people age, this proficiency decreases. Language development begins very...

Development of the Lymphatic System

Development of the Lymphatic System

The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sub-RDT Plasmodium vivax infections and G6PD deficiency in Kayin State, Myanmar.

Malaria journal·2026

Same author

Mortality and Length of Stay Associated With Community-Acquired Escherichia coli and Staphylococcus aureus Bloodstream Infections: An Observational Study in 9 Low- and Middle-Income Countries.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co-Infected With HIV.

Tropical medicine & international health : TM & IH·2026

Same author

Methylene blue retains in vitro activity against early ring-stage artemisinin-resistant Plasmodium falciparum.

Malaria journal·2026

Same author

Bacterial quantitation in clinical infection: a systematic review.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026

Same author

Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia.

Nature medicine·2026

Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026

Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026

Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026

Same journal

Relacorilant: First Approval.

Drugs·2026

Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026

Same journal

Linerixibat: First Approval.

Drugs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 10, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

Drugs in Development for Malaria.

Elizabeth A Ashley^1,2, Aung Pyae Phyo³

¹Myanmar Oxford Clinical Research Unit, Yangon, Myanmar. liz@tropmedres.ac.

|May 27, 2018

Summary

This summary is machine-generated.

New antimalarial drugs are urgently needed due to Plasmodium falciparum resistance. Several promising agents are in clinical development, including novel combinations and treatments for severe malaria and relapse prevention.

More Related Videos

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes

Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes

Published on: July 4, 2007

Related Experiment Videos

Last Updated: Feb 10, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes

Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes

Published on: July 4, 2007

Area of Science:

Drug Discovery and Development
Infectious Diseases
Parasitology

Background:

Antimalarial drug development has accelerated, driven by product development partnerships.
Emerging resistance to artemisinin derivatives, piperaquine, and mefloquine in Southeast Asia necessitates urgent development of new antimalarials.
The malaria burden is predicted to remain high, underscoring the continuous need for novel therapeutic agents.

Purpose of the Study:

To review the current landscape of antimalarial drug development.
To highlight key agents in clinical trials for uncomplicated and severe malaria, and for Plasmodium vivax relapse prevention.
To discuss the challenges and future directions in antimalarial combination therapy.

Main Methods:

Review of current antimalarial agents in clinical development.
Analysis of leading candidates in various phases of clinical trials.
Discussion of challenges including drug resistance and specific population use.

Main Results:

Over 13 antimalarial agents are in clinical development, primarily blood schizonticides for uncomplicated falciparum malaria.
Artefenomel-ferroquine and lumefantrine-KAF156 are leading candidates in Phase 2b.
Tafenoquine is under regulatory review for Plasmodium vivax relapse prevention, offering a single-dose alternative to primaquine.

Conclusions:

New antimalarials are crucial due to widespread resistance and the persistent malaria burden.
Current treatment for severe malaria relies on artesunate and quinine, with sevuparin as an adjuvant.
Future strategies may involve three- or multi-drug combinations to combat resistance and improve treatment efficacy.